Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety,
tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or
refractory B-cell malignancies. LP-168 is a small molecule inhibitor.